Trials / Recruiting
RecruitingNCT07330245
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
DAHLIA: Achievement of Low Level of Disease Activity With a Dose of Corticosteroids Less Than or Equal to 5 mg (LLDAS5): a Real-life Study With Anifrolumab on Patients With Systemic Lupus Erythematosus in Italy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 218 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5
Detailed description
DAHLIA study aims to expand real-world evidence on anifrolumab role in clinical practice, specifically evaluating its effectiveness in achieving and maintenance of LLDAS with a dose of corticosteroids less than or equal to 5 mg/day (LLDAS5). Moreover it will provide data on corticosteroid tapering strategies. Additionally, will be also evaluated the Definitions Of Remission In SLE (DORIS) remission during the study period, as well as the depressive symptoms of these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Anifrolumab | anifrolumab - fully human monoclonal antibody target type I INF |
Timeline
- Start date
- 2025-12-31
- Primary completion
- 2028-09-30
- Completion
- 2028-09-30
- First posted
- 2026-01-09
- Last updated
- 2026-04-03
Locations
19 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT07330245. Inclusion in this directory is not an endorsement.